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Diagnostic and treatment standards in idiopathic pulmonary 
fibrosis in the era of antifibrotic drugs in Poland: A real-world 
practice survey
Abstract
Introduction: Currently, only two drugs have been shown to modify the inevitable natural history of idiopathic pulmonary fibrosis 
(IPF). Changes in the reimbursement policy for antifibrotic drugs in Poland have led to the availability of pirfenidone from January 
2017 and nintedanib from March 2018 for the treatment of Polish patients with IPF. This study aimed to evaluate the possible 
changes and shortcomings in the clinical practice standards in IPF in the era of access to antifibrotic therapy in Poland.
Material and methods: A real-world data survey was performed among physicians attending the Polish Respiratory Society 
Congress held in May 2018. The present survey was a follow-up to the previous survey undertaken in 2016, before the availability 
of antifibrotics in Poland.
Results: A total of 99 physicians participated in the survey, among which 80% were pulmonologists. The majority of participants 
(83%) represented hospital-based clinicians and most of them (93%) were involved in interstitial lung diseases (ILD) management. 
As many as 63% of the respondents elaborate the final diagnosis of IPF working with the expert radiologist routinely, 47% do that 
in the cooperation with other pulmonologists, and if a biopsy was performed 39% discuss its results with the expert pathologist. 
Bronchoalveolar lavage (BAL) and surgical lung biopsy (SLB) would never be recommended in the differential diagnosis of IPF by 
9% and 16% of the respondents, respectively. Corticosteroids (CS) or a combination of CS and immunosuppressants (IS) is still 
recommended by 22% of participants. Proton pump inhibitors (PPI) in the case of symptomatic GERD are prescribed by 44% of 
the respondents, and 12% prescribe PPI regardless of GERD symptoms. Pirfenidone is used by 70%, and nintedanib by 48% of the 
respondents. Only 39% of the respondents refer patients with IPF to professional rehabilitation centers. 
Conclusions: The level of cooperation between pulmonologists and other specialists in the diagnostic workup of IPF is unsa-
tisfactory. IPF treatment practices in the era of access to effective drugs in Poland require immediate improvement. There is an 
urgent need to develop the local Polish practical guidelines to improve the management of IPF. 
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a spe-
cific form of chronic, fibrosing and progressive 
idiopathic interstitial pneumonia (IIP) that occurs 
primarily in older adults. IPF is characterized by 
histopathologic and/or radiologic pattern of usu-
al interstitial pneumonia (UIP) [1]. The disease 
represents one of the most common interstitial 
lung diseases (ILD) [2]. The clinical course of 
IPF is variable and unpredictable, nevertheless, 
median survival is known to be between 2.5 to 
3.5 years, yet some patients live much longer 
[3]. According to the actual international clinical 
practice guidelines IPF may be diagnosed based 
on the presence of a radiologic pattern of UIP on 
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high-resolution computed tomography (HRCT) of 
the lungs after careful exclusion of known causes 
of pulmonary fibrosis. In the case of other than 
typical radiographic UIP pattern on HRCT of the 
lungs (probable UIP, indeterminate for UIP or al-
ternative diagnosis) a surgical lung biopsy (SLB) 
is recommended for confirmation of the presence 
of histopathologic UIP pattern for definite IPF 
diagnosis [1]. 
For patients with newly detected interstitial 
lung disease (ILD) of unknown cause, who are 
suspected of having IPF, multidisciplinary dis-
cussion (MDD) is suggested for the diagnostic 
decision-making process. It is recommended that 
the multidisciplinary team (MDT) involved in the 
diagnostic process of IPF and serving for MDD 
should consist of pulmonologist, radiologist, and 
pathologist. Participants of MDT should have ex-
pert knowledge and experience in the differential 
diagnosis of ILD. Therefore, the diagnosis of IPF 
should be undertaken in ILD reference centers. 
Benefits of the direct interaction during MDD in 
the diagnostic work-up of IPF include a shorter 
delay for the correct diagnosis and therapy, limita-
tion of additional, unnecessary diagnostic testing 
and incorrect therapies [1].
Historically used pharmacotherapy for IPF 
including corticosteroids (CS), immunosuppres-
sants (IS), N-acetylcysteine (NAC) or combination 
triple therapy including CS, azathioprine (AZA) 
and NAC is nowadays strongly contraindicated 
due to the lack of benefit and increased number 
of adverse effects [4]. Based on the several sup-
positions of the potential role of gastroesophageal 
reflux (GER) in IPF pathogenesis and progression, 
actual international practice guidelines recom-
mend that all patients should be treated with 
antacid therapy (AAT), which may decrease the 
risk for microaspiration-associated lung injury or 
damage, a mechanism that has been postulated to 
cause or worsen IPF. AAT treatment is suggested 
by the international IPF treatment guidelines 
regardless of whether GER symptoms are clini-
cally apparent or not [4]. Non-pharmacological 
interventions, such as supplemental oxygen 
therapy, pulmonary rehabilitation programs, and 
lung transplantation are also recommended in the 
holistic management of IPF. 
Currently, only two drugs have been shown 
to modify the inevitable disease course. Pirfeni-
done and nintedanib, independently, have been 
shown to slow the disease progression limiting 
the decline of lung function in patients with IPF 
[5, 6]. The European Medicine Agency (EMA) 
registered pirfenidone in 2011 and nintedanib in 
2015 for the treatment of IPF. Both medications 
are recognized as an actual standard of pharma-
cological treatment of the disease [4]. Changes in 
the reimbursement policy for antifibrotic drugs 
in Poland have led finally to the availability of 
pirfenidone from January 2017 and nintedanib 
from March 2018 for the treatment of Polish pa-
tients with IPF. 
Despite the availability of effective pharma-
cological treatment options for IPF patients in 
Poland, local evidenced-based diagnostic and 
therapeutic standards established for Polish IPF 
patients with regards to the specificity of the na-
tional health service system and specific patients’ 
needs and expectations are lacking. The previous 
survey on common practices of the Polish physi-
cians in the management of IPF, undertaken before 
the availability of antifibrotic therapy in Poland, 
pointed out unsatisfactory local diagnostic and 
therapeutic standards in IPF [7]. 
The present real-world practice survey aimed 
to collect follow-up data regarding possible 
changes and shortcomings in the clinical practice 
standards in IPF diagnosis and treatment in the 
era of access to the antifibrotic therapy for Polish 
patients with IPF.
Material and methods
Physicians attending the Polish Respiratory 
Society Congress held in May 2018, representing 
mostly pulmonologists and other professionals 
involved in the management of different fields of 
respiratory medicine, were invited to participate 
in the study. The self-prepared questionnaires 
consisting of 20 questions divided into 3 parts: 
1. Data describing the responding physician; 
2. Diagnosis of IPF; and 3. Treatment of IPF were 
distributed at the entrance to the lecture room 
during the ILD sessions of the congress and 
collected at the end of the session. All collected 
categorical data are presented as absolute num-
bers and relative frequencies (n, %). Continuous 
data are expressed as mean with standard devia-
tion (SD). For data clarity percentage values are 
rounded to the nearest whole number. 
Results
Characteristics of participants
A total of 99 physicians participated in the 
survey. Summary of characteristics of study par-
ticipants is shown in Table 1. The most prevalent 
group of respondents (38%) were in the age be-
tween 41 and 50 years old. Pulmonary medicine 
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as the medical specialty was declared by 80% of 
the respondents (68% of pulmonologists report-
ed having also an internal medicine specialty), 
and 11% were general internists only, without 
completed additional specialization. The other 
respondents’ specializations included: family 
medicine (5%; 3 out of 5 family doctors had basic 
specialization in pulmonary medicine), allergolo-
gy (6%; 5 out of 6 allergists had basic specializa-
tion in pulmonary medicine), 3% declared being 
pediatricians, 2 out of 3 having pulmonology as 
the basic specialization. The university hospital 
or research institute was the main place of work 
for 45% of the respondents, and 42% of them were 
joining it with outpatient pulmonary medicine 
practice. The non-academic hospital was the 
main place of work for 38% of the respondents, 
and 45% of them were joining inpatient with out-
patient practice. Sole outpatient pulmonary de-
partment as the main place of work was declared 
by 12% of the respondents. A significant majority 
of respondents (70%) declared experience in the 
field of pulmonary medicine exceeding 10 years. 
The distribution of professional experience in 
the area of pulmonary medicine is summarized 
in Table 1. 
Table 1. Characteristics of respondents
Question Answer  n  %#
Age [years] < 30  2  2
30–40  18  18 
41–50  38  38
51–60  33  33
> 60  8  8
Specializations* None  5  5
Internal medicine  70  70
Pulmonary medicine  79  80
Allergology  6  6
Family medicine  5  5
Other  3  3
Place of work* Hospital — academic/research center  45  45
Hospital — non-academic/non-research center  38  38
Pulmonary Diseases Outpatient Clinic  48  48
Family medicine practice  18  18
Other  7  7
Professional experience in pulmonary medicine [years] < 5  16  16
6–10  12  12 
11–20  33  33
21–30  29  29
31–40  7  7
 > 40  1  1
Involved in ILD diagnosis and treatment? Yes  63  63
Sometimes  30  30
Never  6  6
If involved — number of IPF patients per year < 5  35  35
6–10  36  36
11–20  17  17
21–30  3  3 
 31-40  5  5
 > 40  2  2
*The sum of particular items does not equal 100%; # rounded to a whole number
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The majority (63%) of respondents declared 
being involved in the diagnosis and treatment of 
ILD routinely, 30% sometimes, and 6% never. Of 
those who declared being involved routinely or 
sometimes, 35% have had below 5 IPF patients, 
36% between 6 and 10, 17% between 11 and 20, 
and 10% over 20 patients with IPF under their su-
pervision in the previous 12 months, see Table 1. 
Those who declared not being involved in the ILD 
diagnosis and treatment (6%) refer patients with 
suspicion of IPF directly to the nearest pulmonary 
medicine department (2 respondents) or refer 
them after having confirmed suspicion of IPF in 
the HRCT examination (4 respondents).
Diagnostic standards
As many as 17% of the respondents agreed, 
that BAL should be performed always in patients 
suspected of IPF, 74% would recommend BAL in 
selected patients, and 9% declared that BAL is 
useless or only of minimal diagnostic value in 
IPF patients, see Figure 1. 
SLB would never be recommended in pa-
tients suspected of IPF by 16% of the respondents, 
would be recommended rarely (in less than 20% 
of cases) by 74%, often (in more than 20% of cas-
es) by 8%, and would be recommended always by 
2% of the respondents, see Figure 2. The majority 
of participants (53%) refer patients suspected of 
having IPF for transbronchial lung cryobiopsy 
(TBLC) rarely (in less than 20 % of cases), 9% do 
that frequently (in > 20% of cases), 1% do that 
always, and 37% of the respondents never refer 
patients with IPF suspicion for TBLC.
Only 1% of the respondents diagnose IPF 
on their own, 10% ask other specialists only in 
case of difficulties, 47% elaborate the final di-
agnosis in the discussion with other pulmonary 
medicine specialists, and 63% ask experienced 
radiologists for advice routinely. In addition, 
when the lung biopsy was performed, 39% of 
the respondents discuss its results with an ex-
perienced pathologist, who is a member of the 
MDT, see Figure 3.
Yes, in all cases
Yes, in selected cases
No
9%
17%
74%
Figure 1. Distribution of answers to the question: Do you agree, that 
bronchoalveolar lavage (BAL) is necessary in the differential diagnosis 
of idiopathic pulmonary fibrosis (IPF)?
Figure 2. Distribution of answers to the question: How often do you 
refer patients with suspicion of IPF for surgical lung biopsy (SLB)?
Figure 3. Distribution of answers to the question: Are you assisted by other specialists in the differential diagnosis of IPF? (multiple choice question)
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Respiratory polygraphy or polysomnogra-
phy examination is never recommended to IPF 
patients by 40% of healthcare professionals, is 
recommended rarely (< 20% of patients) by 51%, 
frequently (> 20% of patients) by 6%, and is rec-
ommended almost always (in > 80% of patients) 
by 3% of the respondents.
Treatment standards
Home oxygen therapy is recommended to all 
patients with IPF by 15% of participating physi-
cians, only in case of exercise-induced hypoxemia 
by 13%, in case of resting hypoxemia by 71%, and 
is never recommended (because of lack of proof 
of its efficacy) by 1% of participants.
Ambulatory oxygen (from portable sources) 
is recommended to all IPF patients by 12%, to all 
IPF patients with exercise-induced hypoxemia by 
46%, to all patients with resting hypoxemia by 
31%, to all IPF patients with exercise-induced 
dyspnea by 5% of the respondents. Due to the lack 
of evidence for its efficacy, 6% of the respondents 
do not recommend ambulatory oxygen at all.
As far as rehabilitation is concerned, 45% 
of the respondents recommend different simple 
forms of activity to IPF patients, whereas 39% 
refer patients to professional pulmonary rehabili-
tation centers. As many as 6% of the respondents 
do not recommend rehabilitation due to the lack 
of evidence of its efficacy in this particular group 
of patients, and 10% do not do that due to the 
lack of access to the rehabilitation centers in the 
vicinity.
As many as 25% of the physicians refer all 
their IPF patients to lung transplantation centers, 
59% of participants refer their patients when 
they notice a significant deterioration in lung 
function test results, 16% never refer patients to 
Figure 4. Distribution of answers to the question: What medications do you use in the treatment of idiopathic pulmonary fibrosis (IPF)? (multiple 
choice question). AZA — azathioprine; CS — corticosteroids; GERD — gastroesophageal reflux disease; IS — immunosuppressive drugs; NAC — 
N-acetylcysteine; PPI — proton pump inhibitors
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lung transplantation centers due to lack of access 
to such centers.
A high dose of CS is still recommended by 
4% of participants, and 5% of them prescribe low 
dose oral steroids or inhaled steroids for symp-
tomatic treatment of cough in IPF. As many as 18% 
still recommend CS and IS. NAC in monotherapy 
or combination with CS or with CS and AZA is 
used by 3% of the respondents. Proton pump in-
hibitors (PPI) in the case of symptomatic GERD 
are prescribed by 44% of the respondents, and 
12% prescribe PPI regardless of GERD symptoms. 
Pirfenidone is used by 70%, and nintedanib by 
48% of the respondents. No treatment is recom-
mended by 7%, and the explanation for this atti-
tude is the lack of access to antifibrotic drugs, see 
Figure 4. None of the respondents declared, that 
antifibrotic drugs are not sufficiently effective or 
present unacceptable profiles of toxicity. 
As many as 72% of the respondents declared 
having under their supervision at least 1 patient 
on pirfenidone therapy. In this subgroup, the 
mean number of IPF patients treated by a single 
healthcare professional with pirfenidone was 4.76 
(7.96). About 38% of the respondents declared 
having under their supervision at least 1 patient 
on nintedanib therapy. In this subgroup, the mean 
number of IPF patients treated by a single health-
care professional with nintedanib was 1.53 (3.06). 
According to 38% of the respondents < 50% 
of patients with IPF are eligible for the treatment 
based on the Polish National Health Fund (NHF) 
qualification criteria for antifibrotic therapy, 33% 
of the respondents estimate that between 50 to 
80% of their IPF patients are eligible, 7% estimate 
that > 80% of patients are eligible. As many as 
13% of the respondents are not familiar with the 
criteria of NHF antifibrotic therapeutic program 
for IPF patients, and 9% are not able to answer 
what percentage of their patients are eligible for 
antifibrotic therapy due to the lack of access to 
all mandatory testing required for patient’s en-
rollment into the treatment program, see Figure 5.
The majority of respondents (64%) esti-
mated, that < 50% of patients referred to NHF 
treatment program receive antifibrotic drugs 
without substantial delay (within 3 months since 
qualification), 13% presume that between 50 to 
80% of patients receive drugs without delay, 7% 
estimate no delay in case of > 80% of patients, 
and 16% declare, that all their patients receive 
drugs without delay.
A 46% of surveyed physicians inform all their 
patients about the IPF Patients Association, which 
provides the support and education for patients 
with IPF and their family members, 19% of the 
respondents inform patients about the associa-
tion only when they are asked. The minority of 
respondents (6%) are not convinced if patients 
need such association, and 29% did not realize, 
that such an association exists.
Discussion
The present real-world data survey on the 
clinical practice standards in IPF diagnosis and 
treatment in the era of access to the antifibrotic 
therapy for Polish patients with IPF is a fol-
low-up to the previous survey on the same topic 
undertaken in 2016, before the availability of 
antifibrotics in Poland [7]. During two years in be-
tween both surveys, the situation has changed for 
Polish patients with IPF in regards to the access 
to effective pharmacological therapy. NHF reim-
bursement for antifibrotic drugs in Poland has led 
to the availability of pirfenidone from January 
Figure 5. Distribution of answers to the question: What percentage of patients with IPF under your supervision qualify for the treatment with anti-
fibrotics based on the Polish National Health Fund (NHF) qualification criteria?
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2017 and nintedanib from March 2018 for the 
treatment of Polish patients with IPF. The present 
survey aimed to determine whether access to 
antifibrotic therapy together with growing aware-
ness of the disease has influenced the diagnostic 
and treatment practices of the Polish healthcare 
professionals in the management of IPF. 
A total of 93% of the respondents declared to 
be involved in the diagnosis and treatment of ILD 
routinely or sometimes which confirms that the 
survey’s targeted population has been adequately 
chosen. The first part of our survey evaluating 
diagnostic standards confirmed that the clinical 
workup of Polish professionals for IPF diagnosis 
has only slightly changed over that time. Com-
pared to the previous survey in which almost 30% 
of the respondents agreed that BAL is necessary 
in all cases in the differential diagnosis of IPF [7], 
in the actual one, only 17% of physicians agreed 
to the same opinion. The majority of respondents 
(74%) use BAL only in selected cases of patients. It 
is worth to mention, that although the 2011 inter-
national evidence-based guidelines for diagnosis 
and management of IPF do not recommend the use 
of BAL in the differential diagnosis [8], the update 
of this document from 2018 gives conditional rec-
ommendation for BAL in patients with other than 
typical UIP pattern in HRCT [1]. The majority of 
respondents in both surveys would recommend 
SLB in selected patients with a suspicion of IPF, 
which is in line with current conditional recom-
mendation for SLB in patients with other than 
typical UIP radiologic patterns [1]. Our results 
point out that TBLC is not a common alternative 
for SLB in the diagnosis of IPF in Poland. More 
than half of the respondents refer patients with 
a suspicion of IPF for TBLC rarely and almost 40% 
never refer them for TBLC. TBLC represents a nov-
el and exciting tool in the diagnostic pathway in 
IPF and offers a potentially safer, less-invasive and 
cheaper alternative to SLB, although less accurate 
[9]. The low use of TBLC in the diagnosis of IPF 
in Poland may be caused by less availability and 
experience with TBLC in our country. While the 
body of evidence regarding the use of TBLC in 
the differential diagnosis of IPF grows, the qual-
ity remains low. The majority of publications are 
retrospective single-center studies, which suffer 
from a significant risk of bias. This is a reason, 
that no recommendation either for or against TBLC 
in the diagnosis of IPF has been made in the up-
dated international recommendations from 2018 
[1]. More rigorous studies with adequate patient 
sample size are warranted to settle the issue of the 
diagnostic utility of TBLC in IPF. 
According to the guidelines, the deci-
sion-making process of the IPF diagnosis should 
involve MDT, including a clinician, radiologist, 
and pathologist. The previous survey findings 
showed significant shortcomings regarding the 
involvement of MDT in the elaboration of IPF 
diagnosis [7]. This situation has not improved 
much in Poland over two years since the previous 
survey was undertaken. Only 8% more of the re-
spondents dealing with IPF differential diagnosis 
(55% in 2016 and 63% in 2018) routinely work 
with and ILD expert radiologist and a similar 
percentage of clinicians (40% in 2016 and 39% in 
2018) discuss the results of biopsy with an expert 
pathologist. MDT is critical for diagnosing cases 
of IPF and other ILD when the HRCT scans and 
clinical workup do not provide a clear diagnosis. 
Previously published data showed that a large 
percentage of patients experience long delays and 
are evaluated by three or more physicians before 
receiving the correct ILD diagnosis [10]. Early and 
accurate diagnosis of IPF through MDT discussion 
is essential to enable the initiation of therapies 
that have the potential to affect inevitable disease 
natural history and the avoidance of inappropri-
ate and potentially harmful drugs [11]. Thus, the 
diagnostic process of IPF should be elaborated in 
the expert ILD centers, where the involvement 
of experienced MDT participants increases the 
diagnostic confidence [12]. It is of note, that more 
than 80% of the participants of the survey were 
hospital-based clinicians representing both aca-
demic and non-academic centers responsible for 
diagnosis and treatment of the broad spectrum of 
the respiratory conditions. Up to date, there is no 
reference center in Poland solely dedicated to ILD 
diagnosis and therapy. The present survey results 
indicate that more efforts are needed to improve 
the MDT approach to ILD diagnosis in Poland. 
In the authors personal opinion, formation of 
experienced MDT in Polish respiratory centers 
involved in ILD diagnosis should become an ac-
tual priority as long as IPF diagnostic standards 
are considered. This is especially important in the 
era of access to effective disease-modifying drugs. 
The second part of our survey focused on 
treatment standards. A radical change has been 
noted in the pharmacological treatment of IPF 
patients in Poland in the meantime between sur-
veys. Pirfenidone and nintedanib have become 
available in the therapeutic program refunded 
by NHF for patients with mild-to-moderate IPF. 
About one-third of the respondents of the first 
survey were not offering pharmacological ther-
apy to patients with IPF because effective drugs 
Advances in Respiratory Medicine 2019, vol. 87, no. 6, pages 221–230 
228 www.journals.viamedica.pl
were not available [7]. In the present survey, the 
majority of the clinicians use antifibrotic drugs in 
the pharmacological treatment of IPF. Only 7% of 
participants believed that effective therapies are 
not available. More of the respondents declared 
experience with pirfenidone (70%) than nintedan-
ib (48%) in the clinical practice, which is proba-
bly a consequence of the earlier reimbursement 
of the first one in Poland. It is of note, that 13% 
of the respondents were not familiar with the 
criteria of NHF antifibrotic therapeutic program 
for IPF patients in Poland and according to the 
majority of the respondents (64%), less than 50% 
of patients referred to NHF therapeutic program 
receive antifibrotics without substantial delay. 
These findings indicate that more attention and 
efforts are needed to minimize delays in accessing 
care by patients with IPF in Poland. In the pre-
vious survey undertaken in 2016 among Polish 
physicians taking care of patients with IPF, before 
the availability of antifibrotics, 24% of the respon-
dents declared the use of CS or combination of CS 
and IS for the treatment of IPF [7]. Surprisingly, 
in the era of access to antifibrotic therapy since 
early 2017, still a total of 22% of the respondents, 
in the actual survey, declare use of high-dose CS 
in monotherapy or a combination of CS and IS for 
the treatment of IPF in 2018. Such pharmacologi-
cal therapy is not recommended by international 
treatment guidelines in IPF released in 2015 due 
to the lack of benefit, significant toxicity, and 
adverse effects [4]. More educational initiatives 
are needed to change inappropriate practices 
in IPF therapy in Poland. It is likely, that Polish 
practical IPF guidelines, which are lacking, could 
improve diagnostic and treatment standards of 
IPF, providing Polish-language physicians a doc-
ument in their language oriented towards clinical 
practice and decision-making process in IPF. 
Similar national initiative in France has led to 
important changes in the diagnosis and practical 
management of IPF by French pulmonologists 
[13]. Widespread awareness of national guidelines 
among French pulmonologists reduced the use of 
CS in monotherapy or combination therapy in 
IPF from 49% in 2011-2012 to 7% in 2014 [13, 
14]. No change has been noted in the prescrip-
tion habits in regards to AAT in IPF in the actual 
survey compared to the previous one [7]. PPI are 
used in the case of symptomatic GERD by 44% 
of the respondents and 12% use PPI regardless of 
GERD symptoms (43% and 11% in the previous 
survey, respectively). Although the potential role 
of gastroesophageal reflux (GER) in IPF pathogen-
esis and progression is not fully explained, it is 
suggested that AAT may decrease the risk for mi-
croaspiration-associated lung injury or damage, 
a mechanism that has been postulated to cause 
or worsen IPF [15]. Based on the encouraging 
retrospective clinical data, that PPI can stabilize 
lung function and reduce disease flares and hos-
pitalizations, the international treatment guide-
lines recommend the use of AAT in IPF with the 
treatment indication being IPF and not GERD [4]. 
However, this recommendation carries very low 
confidence in effect estimates. On the contrary, 
recent studies not only question the relevance of 
the above mention retrospective findings but also 
associate the use of PPI with an increased risk of 
lung infections and a negative prognostic outcome 
[15]. Therefore, AAT prospective randomized 
trials in IPF are urgently needed. 
As long as non-pharmacological therapy in 
IPF is concerned, the international guidelines 
recommend supplemental oxygen, pulmonary 
rehabilitation programs, and lung transplanta-
tion [4]. According to our results, non-pharma-
cological treatment practices have not changed 
substantially over two years between the surveys. 
The majority of respondents would recommend 
home oxygen therapy for IPF patients with rest-
ing hypoxemia (83% in 2016 and 71% in 2018) 
[7]. Although, guidelines recommend the use of 
supplemental oxygen in IPF patients with sig-
nificant resting hypoxemia, specific criteria for 
oxygen indication in IPF are not established [4]. 
For the clinical practice in this matter criteria 
for the long-term oxygen therapy (LTOT) estab-
lished for chronic obstructive pulmonary disease 
(COPD) patients based on two landmark studies 
conducted in the late 1970s, which demonstrat-
ed a survival benefit of LTOT in severe COPD 
associated with resting hypoxemia, are widely 
adopted [16, 17]. Although, no convincing data 
exist if similar to observed in COPD cohorts LTOT 
survival benefit translates to patients with IPF. 
Nevertheless, supplemental oxygen therapy may 
improve symptoms and exercise tolerance in IPF 
patients without resting hypoxemia [18]. The ma-
jority of respondents seem to know this relation 
and would recommend ambulatory oxygen (from 
portable sources) for the symptomatic therapy of 
patients with IPF. 
Pulmonary rehabilitation programs are an ev-
idence-based recommendation for the non-phar-
macological treatment of patients with different 
chronic respiratory diseases, especially COPD, 
but also IPF [1]. The benefits of pulmonary re-
habilitation in IPF include improved symptoms, 
especially dyspnea, increased exercise tolerance 
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and level of physical activity [19, 20]. Moreover, 
these benefits translate then to a lower level of 
anxiety and depression and therefore increased 
quality of life of IPF patients. Nevertheless, the 
majority of respondents of both the surveys 
would recommend only different simple forms 
of activity to IPF patients (74% in 2016 and 45% 
in 2018), and the minority of them would refer 
patients to professional pulmonary rehabilitation 
centers (21% in 2016 and 39% in 2018) [7]. Poorly 
developed network of pulmonary rehabilitation 
centers in Poland (only a few centers in the whole 
country) resulting in significant shortcomings 
to access to this type of non-pharmacological 
management of patients with IPF are probably 
responsible for the above clinical practices of 
Polish physicians. Pulmonary rehabilitation must 
be included in the integrative treatment of IPF, 
taking into consideration an inevitable disease 
course and only a modest response to new drugs. 
Better access to the rehabilitation programs is an 
unmet need in non-pharmacological therapy of 
patients with IPF in Poland. 
Despite the advances in recent years in the 
treatment of IPF it continues to be a progressive 
disease with poor prognosis. In selected patients, 
lung transplantation may be a treatment option, 
with optimal results in survival and quality of 
life. Currently, pulmonary fibrosis is the main 
indication for lung transplantation [21]. How-
ever, mortality on the waiting list among these 
patients is high, since many patients are referred 
to the transplant centers with advanced disease. 
Therefore, all patients with IPF without contra-
indications should be referred to a transplant 
center early for evaluation. Based on our results, 
we noted a significant change in the approach 
to lung transplantation in IPF over two years in 
Poland. In 2016 almost one-third (31%) of the 
respondents would not refer patients for lung 
transplantation due to poor access to transplan-
tation centers, whereas in 2018 only 16% of the 
respondents admitted to such practice. Better 
cooperation between pulmonary departments 
and transplantation units in Poland is crucial for 
optimal patients outcomes. 
The results of the comparison of the present 
follow-up survey assessing possible changes and 
shortcomings in clinical practice standards in 
the management of IPF patients with a similar 
survey undertaken in 2016 must be considered in 
the context of obvious limitations. Both surveys 
were not exactly the same, and fewer physicians 
were surveyed in 2018 (99 vs 150). We did not 
control if participants of the second survey were 
participating in the first one, as both surveys were 
voluntary and anonymous. Nevertheless, we con-
sider both surveys participants as a representative 
sample of motivated Polish physicians taking care 
of patients with IPF, and the findings commented 
above as a broad picture of changes that occurred 
between 2016 and 2018, not limited to change in 
the access to antifibrotic therapy.
Conclusions
Taken together, Polish physicians responsible 
for the management of patients with IPF are aware 
of the most important current international guide-
lines diagnostic recommendations. The level of 
cooperation between pulmonologists and other 
specialists to confirm the diagnosis of IPF, in the 
context of MDT work-up, is unsatisfactory. The 
treatment practices in the era of access to effective 
drugs in Poland require immediate improvement. 
There is an urgent need to develop national 
Polish practical guidelines for IPF which will 
offer Polish-speaking physicians and authorities 
an evidenced-based source document in their 
language oriented towards clinical practice and 
decision making for the best outcomes in the 
management of IPF. 
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